Full Press Release Details
REGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS FDA Grants Fast Track Designation to the VEGF Trap for Specific Cancer Indication.
REGN
REGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS FDA Grants Fast Track Designation to the VEGF Trap for Specific Cancer Indication
Key Takeaway: REGENERON REPORTS THIRD QUARTER FINANCIAL AND OPERATING RESULTS FDA Grants Fast Track Designation to the VEGF Trap for Specific Cancer Indication
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema